local_hospital

Nemocnice Trebic příspěvková organizace

Address
lock Available on a paid plan

Nemocnice Trebic příspěvková organizace - Wound Healing & Regenerative Medicine

Nemocnice Trebic příspěvková organizace is a clinical research facility engaged in advanced therapeutic approaches for challenging wound care conditions. The center contributes to cutting-edge investigations in regenerative medicine, focusing particularly on therapy-resistant conditions that require innovative treatment strategies.

  • Stem cell therapies for non-healing venous leg ulcers
  • Chronic venous ulcer (CVU) management and treatment
  • Regenerative medicine applications in wound healing

The facility participates in pivotal clinical trials evaluating novel allogeneic stem cell treatments for patients with therapy-resistant chronic venous ulcers. Their research emphasizes both efficacy outcomes, including complete wound closure monitoring, and comprehensive safety assessments to advance treatment options for patients suffering from long-term, non-healing wounds that have not responded to conventional therapies.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
3
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 634 other sites in Czechia

description
Trial volume
2
Outperforms 44% of sites
public
Therapeutic diversity
2areas
Outperforms 63% of sites
groups
Sponsor diversity
2sponsors
Outperforms 50% of sites

Therapeutic Area Benchmark — Czechia

Select a therapeutic area to compare against other sites in Czechia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Czechia

Market Share

Country: Czechia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Nemocnice Trebic příspěvková organizace

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety of Allogeneic Skin-Derived ABCB5-Positive Dermal Mesenchymal Stromal Cells in Therapy-Resistant Chronic Venous UlcersRheacell GmbH & Co. KGPhase IIINot RecruitingJan 2025

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells1Unknown2025-01-162025-01-16

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.